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Abstract
Background: The aim of the study was to characterize synovial cells from OA synovium with low-grade and
moderate-grade synovitis and to define the role of synovial macrophages in cell culture.
Methods: Synovial tissue explants were analyzed for the expression of typical markers of synovial fibroblasts (SF),
synovial macrophages (SM) and endothelial cells. Synovial cells at passage 1 (p.1) and 5 (p.5) were analyzed for
different phenotypical markers by flow cytometric analysis, inflammatory factors by multiplex immunoassay,
anabolic and degradative factors by qRT-PCR. P.1 and p.5 synovial cells as different cell models were co-cultured
with adipose stem cells (ASC) to define SM effects.
Results: Synovial tissue showed a higher percentage of CD68 marker in moderate compared with low-grade
synovitis. Isolated synovial cells at p.1 were positive to typical markers of SM (CD14, CD16, CD68, CD80 and CD163)
and SF (CD55, CD73, CD90, CD105, CD106), whereas p.5 synovial cells were positive only to SF markers and showed
a higher percentage of CD55 and CD106. At p.1 synovial cells released a significantly higher amount of all
inflammatory (IL6, CXCL8, CCL2, CCL3, CCL5) and some anabolic (IL10) factors than those of p.5. Moreover, p.1
synovial cells also expressed a higher amount of some degradative factors (MMP13, S100A8, S100A9) than p.5
synovial cells. Co-culture experiments showed that the amount of SM in p.1 synovial cells differently induced or
down-modulated some of the inflammatory (IL6, CXCL8, CCL2, CCL3, CCL5) and degradative factors (ADAMTS5,
MMP13, S100A8, S100A9).
Conclusions: We found that p.1 (mix of SM and SF) and p.5 (only SF) synovial cells represent two cell models that
effectively reproduce the low- or moderate-grade synovitis environment. The presence of SM in culture specifically
induces the modulation of the different factors analyzed, confirming that SM are key effector cells.
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Background
Osteoarthritis (OA) is defined as a disease of the whole
joint because it affects not only the cartilage but the sub-
chondral bone and the synovial tissue that undergo struc-
tural and metabolic modifications [1, 2]. Different reports
have recognized the importance of synovial inflammation
as a key factor associated with the pain and symptoms of
OA, even in the early phase of the disease [3–5]. New im-
aging techniques (ultrasound and magnetic resonance im-
aging) demonstrate synovitis with effusion in 95 % of
patients with OA and synovitis without effusion in 70 % of
patients [6]. A recent report has identified a gene expres-
sion pattern of cells from inflamed and non-inflamed
areas of synovial tissue in OA [7].
Synovial inflammation is a process characterized by
synovial thickening (hypertrophy and hyperplasia) and cell
infiltration (lymphocytes and macrophages) [8, 9]. Histo-
logical analysis of synovium in OA shows an increased
number of lining cells and infiltrating cells, mainly
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consisting of macrophages [8, 10] with a very low percent-
age of B and T cells [11]. Synovial inflammation is now ac-
cepted as an important feature of the symptoms and
progression of OA [6].
Normal synovial layers in OA are composed of syn-
ovial fibroblasts (SF) and inflammatory leukocytes (lym-
phocytes and macrophages) [12]. SF are mesenchymal
cells that display many characteristics of fibroblasts, in-
cluding vimentin, CD55, CD90, cadherin-11, vascular
adhesion molecule-1 (VCAM-1) and intracellular adhe-
sion molecule-1 (ICAM-1) [13–15]. SF constitutively
produce IL6, chemokine (C-X-C motif ) ligand (CXCL)8/
IL8, chemokine (C-C motif ) ligand (CCL)2/monocyte
chemotactic protein (MCP-1), transforming growth fac-
tor (TGF)β, and fibroblast growth factor [13]. Moreover,
synovium was recently reported to contain cells that,
after isolation and cell-culture expansion, display a mes-
enchymal stem cell (MSC) phenotype indistinguishable
from SF [15]. Synovial macrophage-like (SM) cells in
OA show a phenotype similar to other resident cell mac-
rophages, including CD11b, CD14, CD16 and CD68, and
they produce the main inflammatory mediators, such as
IL1, IL6, TNFα, matrix metalloproteinases (MMPs) and
aggrecanases (ADAMTS), which contribute to articular
matrix degradation [16]. Isolated synovial cells in OA
are mainly composed of SF with 7 % SM, less than 0.5 %
neutrophils and less than 0.1 % T cells [17]. It has been
shown that depletion of CD14-positive SM results in a
decline in IL1β and TNFα, thus indicating that these
cells play a role in inflammation [17]. In the early stage of
OA, a unique chemokine signature has been associated
with synovial inflammation [3, 18]. CCL5/RANTES and
CCL19/macrophage inflammatory protein (MIP)3β che-
mokines are mainly associated with inflammation [19].
Up to now there has been no in-depth characterization
of the synovium and isolated synovial cells in OA. Re-
cent papers [20, 21] have highlighted the importance of
better characterization of synovial cells to elucidate the
relationship between the different cell types to better de-
fine an in vitro cell model. This characterization might
lead to better understanding of the interplay between
cells in inflammatory and non-inflammatory conditions,
to define a synovial cell model as a foundation for devis-
ing tailored therapeutic intervention.
To gain new insight into this topic we first analyzed
synovial tissue biopsies for the expression of typical
markers of SF, SM and endothelial cells and then we
followed their expression in isolated synovial cells both
at passage 1 (mix of SF and SM), and passage 5 (SF).
Subsequently, we performed in-depth analysis of isolated
cells for different phenotypical markers, inflammatory,
anabolic and degradative factors. Finally, as inflamma-
tion induces adipose stem cells (ASC) to exert anti-
inflammatory effects [22], we used these cells to test
whether in co-culture experiments the presence of SM
in synovial cells differently induced or down-modulated
some of the inflammatory (IL6, CXCL8/IL8, CCL2/
MCP-1, CCL3/MIP1-α, CCL5/RANTES) and degrada-
tive factors (ADAMTS5, MMP13, S100A8, S100A9) ana-
lyzed. We found that SM in culture induces the specific
modulation of the different factors analyzed, thus con-
firming that SM are key effector cells.
Methods
Patient characterization
Synovial tissues were obtained from 26 patients with OA
(14 women and 12 men, mean age 66 ± 11.10 years, body
mass index 28 ± 4.45 Kg/m2, disease duration 7 ± 4.8 years)
and Kellgren/Lawrence grade 3/4 [23], who were undergo-
ing total knee replacement surgery. Subcutaneous abdom-
inal fat was obtained from six healthy patients undergoing
liposuction. The study was approved by the Rizzoli
Orthopaedic Institute ethical committee and all patients
provided informed consent (Protocol number 15274).
Synovial tissue characterization
Synovial tissue specimens were fixed in B5 solution
(freshly prepared 9:1 mixture of mercuric-chloride/40 %
formaldehyde) at room temperature for 2 h and embed-
ded in paraffin, and serial tissue sections (4 μm thick)
from each specimen were prepared and routinely stained
with hematoxylin-eosin. The histopathological features
of each synovial tissue specimen were evaluated accord-
ing to the synovitis inflammation scoring system de-
scribed by Krenn [24], which rank each of the alteration
evaluated (hyperplasia of the synovial lining layer, in-
flammatory infiltrate and stromal cell density) on a scale
from 0 to 3. The parameters of synovitis inflammation
scoring system were summarized as follows: 0–1 no
synovitis; 2–3 low-grade synovitis; 4–6 moderate-grade
synovitis; and 7–9 high-grade synovitis. The scoring was
performed by two independent observers (CM and GL).
Immunohistochemical analysis of synovial tissue
Serial sections were incubated overnight at 4 °C with
monoclonal anti-human-CD55 (2.5 μg/ml, Millipore,
Temecula, CA, USA), −CD68 (10 μg/ml, Dako Cytoma-
tion, Denmark), −Factor VIII (10 μg/ml Dako), −CCL3/
MIP1α (2.5 μg/ml R&D Systems, Minneapolis, MN, USA)
and -S100A8 (4.5 μg/ml R&D) diluted in Tris-buffered
saline (TBS) containing 0.1 % bovine serum albumin
(BSA). Samples were then rinsed in TBS and sequentially
incubated at room temperature for 20 minutes with multi-
linker biotinylated secondary antibody (Biocare Medical,
Walnut Creek, CA, USA) and alkaline phosphatase-
conjugated streptavidin (Biocare Medical). The reactions
were developed using fast red substrate (Biocare Medical),
counterstained with hematoxylin, and mounted in glycerol
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gel. Negative controls were performed using isotype control
(Dako Cytomation). Semiquantitative analysis of immuno-
histochemically stained slides were performed on 20 micro-
scopic fields (×200 magnification) for each section. The
analysis was performed using Red/Green/Blue (RGB) with
Software NIS-Elements and Eclipse 90i microscope (Nikon
Instruments Europe BV). Briefly, we acquired the total
number of blue-stained nuclei and the total number of
positive-stained red cells. The data were expressed as per-
centage of positive cells for CD55 and CD68, respectively.
For Factor VIII analysis we counted the number of positive
vessels in 20 microscopic fields. The data were expressed as
the mean number of positive vessels/5 mm2 area.
Isolation and characterization of synovial cells from non-
digested fragments
Synovial cells were isolated following a standardized pro-
cedure as previously described. [25] and were used for
the experiments at both passages 1 and 5. Briefly, syn-
ovial tissue was fragmented and the pieces cultured for
7 days. Cultured synovial fragments were removed and
fixed as described above. Synovial cells were grown in
OPTIMEM culture medium (Life Technologies Italia,
Monza, Italy) supplemented with 100 U/ml penicillin
and 100 μg/ml streptomycin in a humidified atmosphere,
at 37 °C with 5 % CO2.
Synovial cells at both passages 1 (p.1) and 5 (p.5) were
characterized by flow cytometry using the following
markers expressed by SF (CD55 (2.5 μg/ml, Millipore),
CD73, CD90, and CD105 (5 μg/ml, BD Pharmingen, San
Jose, CA, USA), CD106 (10 μg/ml, Millipore), SM (CD14
and CD16 (5 μg/ml, Dako), CD68 (5 μg/ml, BD), CD80
(2 μg/ml, GeneTex Inc., Irvine, CA, USA), and CD163
(10 μg/ml, Abcam, Cambridge, UK)), and by endothelial
(CD31, 2 μg/ml, R&D) and mononuclear cells (CD3,
CD34, and CD45 (5 μg/ml, Dako). Briefly, after harvesting
cells upon detachment, they were washed twice with PBS,
centrifuged, and washed in a flow cytometry buffer (PBS
supplemented with 2 % BSA and 0.1 % sodium azide).
Aliquots of 1 × 105 cells were then incubated with pri-
mary antibodies at 4 °C for 30 minutes, washed twice
with a flow cytometry buffer, and incubated with poly-
clonal rabbit anti-mouse immunoglobulins/fluorescein
isothiocyanate (FITC) conjugate (Dako Cytomation) at
4 °C for 30 minutes. After two final washes, the cells
were analyzed using a fluorescence-activated cell sorting
(FACS) CantoII Cytometer (Becton Dickinson). For iso-
type control, non-specific mouse IgG was substituted for
the primary antibody.
Passage 1 and 5 synovial cells as specific cell models for
cell co-culture
Synovial cells at both passages 1 and 5 (100,000 cells/
well) were seeded in the lower chamber of a 6-well plate
and co-cultured with clinical grade ASC (100,000 cells
in Transwells®) for 7 days (medium was changed at day
2) in complete DMEM using a defined cell ratio (1:1)
that assures no cell proliferation, as we previously re-
ported [22]. ASC were isolated from subcutaneous ab-
dominal fat according to Good Manufacturing Practice
(GMP) [26], and were grown in αMEM supplemented
with platelet lysate (PLP) and characterized for the CD
markers CD14, CD34, CD45, CD73, CD90 (5 μg/ml, BD
Pharmingen) and CD13 (1 μg/ml, eBioscience, San
Diego, CA, USA) as we previously described [22, 26]
(data not shown). Control cells were mono-cultures of
ASC and synovial cells at both passages 1 and 5. The
cells were harvested on day 7 for quantitative RT-PCR
analysis and supernatant stored at −80 °C. The concen-
trations of IL6, CXCL8/IL8, CCL2/MCP-1, CCL3/MIP1-
α, and CCL5/RANTES were analyzed in the supernatant
for all conditions tested as described above.
Cytokine and chemokine release in supernatants
The concentrations of IL1β, IL4, IL6, CXCL8/IL8, IL10,
CCL2/MCP-1, CCL3/MIP1α, CCL5/RANTES, TGFβ,
and TNFα were simultaneously evaluated in the super-
natants of ASC, synovial cells at both passages (1 and 5)
in mono- and co-cultures, using multiplex bead-based
sandwich immunoassay kits (BioRad Laboratories Inc.,
Segrate, Italy) following the manufacturer’s instructions.
Briefly, we added 50 μl to each well of the diluted stan-
dards (fourfold dilution series), controls, and samples in
triplicate and added 50 μl of coupled beads, and the
plate was incubated at room temperature for 30 minutes.
The plate was then washed three times with 100 μl of
wash buffer and incubated with 25 μl of detection anti-
bodies for 30 minutes. Finally, the plate was washed
three times and incubated with 50 μl of streptavidin-PE
for 30 minutes and measured in a reader (Luminex Bio-
plex system, Bio-Rad Laboratories Inc.).
Real-time quantitative reverse transcription polymerase
chain reaction (qRT-PCR) analysis
Total RNA was extracted from human ASC, synovial
cells in mono- and co-cultures, using RNA PURE re-
agent (Euroclone Spa, Pero, Italy) according to the man-
ufacturer’s instructions, and then was treated with
DNase I (DNA-free Kit, Life Technologies). Reverse
transcription was performed using SuperScript VILO
(Life Technology) reverse transcriptase and random hex-
amers, following the manufacturer’s protocol.
Forward and reverse oligonucleotides for PCR amplifi-
cation of ADAMTS4, ADAMTS5, MMP13, S100A8, and
S100A9 are described in Table 1, and real-time PCR was
run as previously described [22]. All primer efficiencies
were confirmed to be high (>90 %) and comparable
(Table 1). For each target gene, messenger RNA (mRNA)
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levels were calculated, normalized to RPS9 according to
the formula 2-ΔCt, and expressed as a percentage of the
reference gene, as this was expressed in the same
amount in all conditions tested.
Statistical analysis
Statistical analysis was performed using non-parametric
tests because the data did not have a normal distribution
(Kolmogorov-Smirnov test). Friedman’s analysis and
Dunn’s post hoc test was used to analyze more than two
groups of paired data, the Mann–Whitney U test was
used to analyze unpaired two-group data and the Wilcoxon
test was used to analyze paired two-group data. Groups
with small samples were evaluated using the exact method.
Values were expressed as the median and interquartile
range. CSS Statistica Statistical Software (Statsoft Inc.,
Tulsa, OK, USA) was used for analysis and values of
p < 0.05 were considered significant.
Results
OA synovial tissue explant characterization
Synovial tissue explants from 26 patients with OA were
first scored on hematoxylin-eosin-stained slides, as re-
ported by Krenn [24] and we found low-grade synovitis
in 4 samples and moderate-grade synovitis in 22 sam-
ples. Vessel proliferation was also evaluated on Factor
VIII-stained slides and there were fewer positive vessels
(90 ± 35/5 mm2 area) in low-grade than in moderate-
grade synovitis (222 ± 79/5 mm2 area). Then, for in-
depth analysis of the main synovial cell populations
present in the synovial tissue, we analyzed CD68 and
CD55 to establish the percentage of synovial macro-
phages and synovial fibroblasts, in both low- and
moderate-grade synovitis. As shown in Fig. 1a, CD68
was mainly positive on synovial macrophages located in
the lining layer and on a few in the sublining layer
(Additional file 1). There were approximately 13 %
and 27 % of CD68-positive cells in low- and moderate-
grade synovitis, respectively (Fig. 1b). The CD55 typical
marker of synovial fibroblast was positive both on the sub-
lining and lining layers (Fig. 1a) (Additional file 1) and was
approximately 70 % positive in both low- and moderate-
grade synovitis (Fig. 1b).
Synovial cells characterization
The cells outgrowing from cultured-synovium tissue
fragments (Fig. 2a) were then morphologically and
phenotypically analyzed. As shown in Fig. 2a, at p.0 cells
started outgrowth from synovial tissue fragments; at p.1
we found two cell types, one spindle-shaped (defined as
synovial fibroblasts, SF) and one with polygonal-star
morphology (defined as synovial macrophages, SM),
whereas at p.5 all cells had only spindle-shaped morph-
ology. Moreover, to confirm that SM and SF had these
peculiar cell morphologies, we immunocytochemically
stained the isolated p.1 and p.5 cells with anti-CD68 and
anti-CD55, typical markers of SM and SF, respectively
(data not shown).
These cells at both passages (p.1 and p.5), were then
characterized by flow cytometry for markers expressed
by SF (CD55, CD73, CD90, CD105, and CD106), SM
(CD14, CD16, CD68, CD80, and CD163), endothelial
cells (CD31), and mononuclear cells (CD3, CD34, and
CD45). As shown in Fig. 2b, p.1 synovial cells had a very
low percentage (<3 %) of CD3, CD31, CD34, and CD45,
an intermediate percentage (10–20 %) of CD14, CD16,
CD68, CD80, CD106 and CD163, and a high percentage
(60–100 %) of CD55, CD73, CD90, and CD105. Interest-
ingly, CD80 and CD163 were expressed (approximately
12 %) only by p.1 synovial cells. Conversely, p.5 synovial
cells had a very low or negative percentage of all the
markers analyzed except for CD55, CD73, CD90, CD105
and CD106. In particular, CD55 and CD106 were the
only markers more highly expressed by p.5 synovial
cells.
Factors released by OA synovial cells
We subsequently evaluated inflammatory factors (IL1β,
TNFα, IL6, CXCL8/IL8, CCL2/MCP-1, CCL3/MIP1α,
and CCL5/RANTES) and anabolic factors (TGFβ, IL4,
and IL10) released by p.1 and p.5 OA synovial cells. As
shown in Fig. 3, p.1 synovial cells produced significantly
more IL6, CXCL8/IL8, CCL2/MCP-1, CCL3/MIP1α,
CCL5/RANTES, and IL10 than those at p.5. IL1β, TNFα,
TGFβ and IL4 were not detected at either passage (p.1
or p.5). In particular, p.1 synovial cells released more
IL6, CXCL8/IL8, and CCL2/MCP-1 than CCL3/MIP1α,
CCL5/RANTES, and IL10. Interestingly, CCL2/MCP-1
Table 1 Oligonucleotide primers used for real-time polymerase chain reaction
Target gene Primers (forward and reverse) Product size (bp) GenBank accession number Primer efficiency (%)
RPS9 GATTACATCCTGGGCCTGAA ATGAAGGACGGGATGTTCAC 161 NM_001013 94.5
ADAMTS4 CTGCCTACAACCACCG GCAACCAGAACCGTCC 293 NM_005099.4 99.1
ADAMTS5 GCACTTCAGCCACCATCAC AGGCGAGCACAGACATCC 187 NM_007038.3 92.4
MMP13 TCACGATGGCATTGCT GCCGGTGTAGGTGTAGA 277 NM_002427 94.5
S100A8 TAGAGACCGAGTGTCCTCA CGCCCATCTTTATCACCAGA 126 NM_002964.4 93.4
S100A9 CCATCATCAACACCTTCCACCA CTGCTTGTCTGCATTTGTGTCC 179 NM_002965.3 91.4
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was the most abundant factor released by p.5 synovial
cells, whereas there was less IL6, CXCL8/IL8, and CCL5/
RANTES. IL10 and CCL3/MIP1α from p.5 synovial cells
were at the limit of detection or not detected, respectively.
OA synovial cell degradative factors
Then we analyzed different factors (ADAMTS4,
ADAMTS5, MMP13, S100A8, S100A9) involved in the
degradation of joint tissue. As shown in Fig. 4, both syn-
ovial cells at p.1 and p.5 expressed the same level of
ADAMTS4, whereas there was significantly more
ADAMTS5 expressed in p.5 than in p.1 synovial cells.
Conversely, MMP13, S100A8, and S100A9 were highly
expressed in p.1 synovial cells, but there was very low ex-
pression of in MMP13 in p.5 synovial cells, and S100A8
and S100A9 were not detected.
Synovial macrophages influence cell co-culture effects
The presence of SM in p.1 synovial cells significantly
increased the release of inflammatory, anabolic and
Fig. 2 Evaluation of isolated passage 1 and passage 5 synovial cells from moderate-grade synovitis in osteoarthritis. a Outgrowth of synovial cells
from synovial non-digested fragments (Passage 0). Passage 1 synovial cells characterized by a mix of cells with a spindle and a polygonal-star
shape. Passage 5 synovial cells characterized only by spindle-shaped morphology. b CD3,CD14, CD16, CD31, CD34, CD45, CD55, CD68, CD73,
CD80, CD90, CD105, CD106, and CD163 immunocytochemical staining on passage 1 and passage 5 synovial cells analyzed by flow cytometry.
Data are expressed as the median and interquartile range (n = 22). *Significant differences between passage 1 and passage 5 synovial cells:
p < 0.005. ND not detected
(See figure on previous page.)
Fig. 1 Characterization of synovial tissue in osteoarthritis (OA). a Representative samples with low-grade (left) and moderate-grade (right) OA
synovitis, stained with hematoxylin-eosin (H&E). Bars 100 μm (magnification × 40). Immunohistochemical analysis of CD55 and CD68 on representative
cases with low-grade (left) and moderate-grade (right) synovitis in OA. Negative control for CD55 and CD68 (Control). Bars 50 μm. b Percentage of
positive cells to CD55 and CD68 analyzed in both low-grade (n = 4) and moderate-grade (n = 22) synovitis in OA. Data are expressed as the median
and interquartile range. *Significant differences between low-grade and moderate-grade synovitis: p < 0.005
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Fig. 3 Evaluation of inflammatory and anabolic factors released by passage 1 (p.1) and passage 5 (p.5) synovial cells from osteoarthritic moderate-
grade synovitis. IL6, CXCL8/IL8, CCL2/monocyte chemotactic protein 1 (MCP-1), CCL3/macrophage inflammatory protein 1α (MIP1α), CCL5/RANTES,
and IL10 were evaluated in the supernatant of both p.1 and p.5 synovial cells as described in “Methods”. Data are expressed as the median and
interquartile range (n = 22). *Significant differences between synoviocytes at p.1 and p.5: p < 0.005
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degradative factors, thus creating a significantly differ-
ent milieu from p.5 synovial cells. Therefore, as p.1
and p.5 synovial cells represent two different cell cul-
ture models, we tested whether they could differently
affect another cell type in co-culture. We chose adi-
pose stem cells (ASC) as the cell model because they
are reportedly activated by an inflammatory environ-
ment [22]. We analyzed inflammatory and degradative
factors, previously tested in basal conditions in p.1 and
p.5 synovial cells (Figs. 3 and 4), after co-culture with
ASC. We did not test IL10 because ASC express and re-
lease large amounts of this cytokine, but did not express
the other factors analyzed (data not shown). As we previ-
ously reported [22], we confirmed that ASC in co-culture
with p.1 synovial cells reduced the release of IL6, CXCL8/
IL8, CCL2/MCP-1, CCL3/MIP1α, and CCL5/RANTES
(Fig. 5a). Conversely, as shown in Fig. 5b, the co-culture of
ASC with p.5 synovial cells (only SF) differently affected
the release of the factors evaluated, thus indicating direct
dependence by the presence of SM in culture. In particu-
lar, ASC when co-cultured with p.5 synovial cells were
able to increase the release of IL6 and CXCL8/IL8, how-
ever they were unable to affect or significantly decreased,
the release of macrophage-like chemokines, such as
CCL2/MCP-1 and CCL5/RANTES, respectively. Interest-
ingly, as shown in Fig. 5b, on p.5 synovial cells the ASC
were unable to modulate CCL3/MIP1α that was still not
released or expressed (data not shown) by SF. Moreover,
as shown in Fig. 5c the analysis of degradative factors
revealed that ASC on p.1 synovial cells decreased the
expression of ADAMTS5, S100A8, and S100A9, but
ADAMTS4 and MMP13 were not affected. Conversely,
ASC on p.5 synovial cells induced the expression of
MMP13 and did not modulate the other factors analyzed
(Fig. 5d).
Moreover, to confirm that the effects observed were
directly dependent on the amount of SM in synovial
cells p.1 we also evaluated all the inflammatory and
degradative factors in p.1 synovial cells isolated from
low-grade synovial explants, which, as shown in Fig. 1b,
contain a very low percentage of SM (CD68 positive). As
shown in Fig. 5e-f, ASC were unable to reduce the in-
flammatory and degradative factors in p.1 synovial cells
from low-grade synovitis, except for CCL5/RANTES
and ADAMTS5, but MMP13 was induced.
Immunohistochemical analysis of CD68, CCL3/MIP1α and
S100A8 on synovial tissue
Furthermore, to confirm that CCL3/MIP1α and S100A8
were specific markers of SM, we also immunostained
serial sections of synovial tissue from patients with mod-
erate synovitis using the positive control macrophage
marker CD68. As shown in Fig. 6, we confirmed that
SM positive to CD68 were also positive to CCL3/MIP1α
and S100A8, which we also detected only on p.1 synovial
cells. Positive cells were mainly located on the lining
layer and around the vessels.
Discussion
Synovitis is a typical feature in a high percentage of
patients with OA, even in the early phase of the disease
[3]. Hyperplasia in the synovium is associated with an
increased number of synovial lining cells in OA,
Fig. 4 Evaluation of degradative factors expressed by passage 1 (p.1)
and passage 5 (p.5) synovial cells from osteoarthritic moderate-grade
synovitis. ADAMTS4, ADAMTS5, MMP13, S100A8, and S100A9 were
evaluated in the supernatant of both p.1 and p.5 synovial cells as
described in “Methods”. Data are expressed as the median and
interquartile range (n = 22). *Significant differences between p.1 and
p.5 synovial cells: p < 0.005. ND not detected
Manferdini et al. Arthritis Research & Therapy  (2016) 18:83 Page 8 of 13
accompanied by infiltration of inflammatory cells mainly
consisting of macrophages [8]. Synovial tissue is a complex
structure mainly composed of SF and SM, and in vitro cell
models have mainly focused on SF. Therefore, we charac-
terized synovial tissue from low-grade and moderate-grade
synovitis and synovial cell outgrowth from cultured non-
digested synovial fragments. These cells were analyzed at
two cell passages (p.1, a mix of SF and SM and p.5, only
SF) to define their phenotype, inflammatory and degrada-
tive factors and their functional role.
Fig. 5 Evaluation of the role of macrophage in cell co-cultures. a-d Co-culture of adipose stem cells (ASC) with passage 1 (p.1) (a, c) and passage
5 (p.5) (b, d) synovial cells from osteoarthritic moderate-grade synovitis and evaluation of released inflammatory (IL6, CXCL8/IL8, CCL2/MCP-1,
CCL3/MIP1α, and CCL5/RANTES) and expressed degradative factors (ADAMTS4, ADAMTS5, MMP13, S100A8, and S100A9). Data are represented as
fold changes versus basal synoviocytes = 1 and expressed as the median and interquartile range (n = 22). *Significant differences between p.1 and
p.5 synovial cells: p< 0.005. e-f Co-culture of ASC with p.1 synovial cells from low-grade osteoarthritic synovitis and evaluation of released inflammatory
(IL6, CXCL8/IL8, CCL2/MCP-1, CCL3/MIP1α, and CCL5/RANTES) (e) and expressed degradative factors (ADAMTS4, ADAMTS5, MMP13, S100A8, and S100A9)
(f). Data are represented as fold changes versus basal synoviocytes = 1 and expressed as the median and interquartile range (n = 4). *Significant differences
between p.1 and p.5 synovial cells: p< 0.005
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Our data show that synovium from patients with OA
and moderate synovitis had approximately 27 % CD68
(SM) and 70 % CD55 (SF) positive cells, which are well-
standardized markers for SM and SF, respectively. The
synovial cells outgrowing in culture were evaluated at
both p.1 and p.5. SF (p.5) were not positive to typical
endothelial (CD31), hematopoietic (CD3, CD34, and
CD45) and macrophage-like markers (CD14, CD16,
CD68, CD80, and CD163) but they expressed more
CD55 and CD106, which are considered relative specific
markers of SF [13]. Moreover, SF at both p.1 and p.5 also
expressed increased amounts of CD73, CD90 and
CD105, which are considered typical markers for identi-
fying mesenchymal stem cells (MSC). In line with sev-
eral reports [14], the isolation of MSC and SF from the
synovium is mainly based on the adhesion properties of
the mononuclear cell fraction in vitro, from which they
can be cultured-expanded as SF. However, detailed stud-
ies, as recently underlined by De Bari [15], are necessary
to determine whether synovium-MSC are SF or different
subsets, as in culture they are indistinguishable and no
markers permit their selective identification. Only p.1
synovial cells were positive to typical macrophage
markers, such as CD14, CD16, and CD68 and to some
specific M1 or M2 macrophage markers, such as CD80
and CD163, thus showing the contemporary presence
of pro-inflammatory M1 type and anti-inflammatory/
regenerative M2 type in the OA synovium. Moreover, in
contrast to other reports, we found the presence of mac-
rophages in p.1 synovial cell culture, which has been re-
ported to be reduced or absent in synovium-derived cells
from digested fragments, and this confirms that enzymatic
digestion affects the recovery of the different cell popula-
tions present in the synovium [14, 20]. Interestingly, p.1
synovial cells express only very small amounts of CD31, a
typical endothelial marker, thus suggesting that this in
vitro procedure does not ensure their isolation.
We found that p.1 synovial cells (mix of SF and SM) re-
lease significantly more IL6, CXCL8/IL8, CCL2/MCP-1,
CCL3/MIP1α, CCL5/RANTES, and IL10 than those of
p.5 (SF), thus suggesting that the absence of SM signifi-
cantly reduces inflammation and does not induce the ana-
bolic factor IL10. It has been shown that CCL2/MCP1
enhances CD106 [27]; our data show an increased number
of positive CD106 on p.5 synovial cells that might be in-
duced by CCL2/MCP1. In fact, even if CCL2/MCP1 is re-
duced compared to that of p.1 synovial cells, it is released
in a greater quantity by p.5 synovial cells.
Bondeson et al. [17] reported that depletion of CD14-
positive SM was associated with a decline in inflamma-
tion associated with decreased IL6, CXCL8/IL8, and
CCL2/MCP-1, which is in line with our data in vitro.
Among the factors analyzed, we found that S100A8,
S100A9, and CCL3/MIP1α were the only undetectable
Fig. 6 Synovial tissue analysis for macrophage markers.
Immunohistochemical analysis of CD68, CCL3/MIP1α, and S100A8
on serial sections for one representative case with moderate-grade
osteoarthritic synovitis. Bars 10 μm
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factors (both at molecular and protein level) in p.5
synovial cells, a cell culture characterized by the absence
of SM, thus confirming that they are specific markers of
SM.
Synovial cells p.1 and p.5 represent two different in vitro
cell models characterized by the presence and absence of
SM, respectively, which are directly responsible for the
low- and high-level inflammatory/degradative milieu. Dif-
ferent studies [28, 29] have used SF (p.5 synovial cells) as
a cell model to test drugs or the effects of other cell types,
without taking into consideration that synovial tissue is
mainly composed of at least two cell types, SM and SF. It
is has been known that OA SM are those mainly respon-
sible for synovial inflammation [5, 16, 30] and it has been
reported that inflammation induces ASC to exert an anti-
inflammatory effect [22, 31, 32]. Therefore, to better
define how the presence or absence of SM in cell culture
influences the effects observed we evaluated the effects of
ASC on inflammation and degradative factors co-cultured
with the synovial p.1 and p.5 cell models. We found that
in contrast with the anti-inflammatory effects found on
p.1 synovial cells from moderate-grade OA, on p.5 syn-
ovial cells the ASC modulated the analyzed inflammatory
factors differently. In particular, ASC significantly induced
IL6 and CXCL8/IL8, decreased CCL5/RANTES, and did
not modulate CCL2/MCP-1 or CCL3/MIP1α, which were
still not expressed or released, thus demonstrating and
confirming a specific dependence of this chemokine on
SM and not on SF. Moreover, it is interesting to note that
among the inflammatory factors analyzed, the CCL5/
RANTES chemokine, mainly associated with a signature
of synovial inflammation, was the only one that was still
down-modulated in the presence of ASC, both in co-
culture with p.1 with low- or moderate-grade synovitis,
and with p.5 synovial cells, thus highlighting that this was
an effect independent of the presence of SM.
It has been shown that CCL3/MIP1α has an important
role in the recruitment of infiltrating leukocytes in the
arthritic joint. Moreover, the CCL3-null mouse arthritis
model is associated with a reduction of infiltrating cells
and normal appearance of the synovium and cartilage,
and the absence of pannus or bone resorption, thus con-
firming the important role of this chemokine in OA
[33]. This evidence is also corroborated by a report of
increased expression and secretion of CCL3-MIP1α
when SF were co-cultured with activated leukocytes
(monocytes or polymorphonuclear neutrophils) [34].
Our data show that ASC in co-culture with p.1 syno-
viocytes from moderate-grade OA decreased the typical
inducible factors ADAMTS5, S100A8, and S100A9, and
did not affect ADAMTS4 and MMP13. Conversely, in
co-culture with p.5 synovial cells they only induced the
expression of MMP13, thus suggesting that in the ab-
sence of SM, SF appear to acquire a characteristic more
typical of SM, such as increased expression of MMP13.
Interestingly, we also found that S100A8 and S100A9,
the main catabolic factors produced by activated macro-
phages, were not detected in p.5 synovial cells co-cultured
with ASC, thus confirming their specific expression on
SM. These data were also confirmed on moderate-grade
OA synovial tissue, where we found that S100A8 and
CCL3/MIP1α were co-expressed with CD68, the typical
macrophage marker.
Moreover, we found that S100A8 and S100A9 inhib-
ition in p.1 synovial cells was also associated with IL6
and CXCL8/IL8 inhibition, which, as already reported
[35], are strictly dependent. These data are also in line
with a recent report that in a murine collagenase-
induced OA model, ASC inhibited synovial activation
mainly by reducing S100A8 and S100A9 [36]. Further-
more, large quantities of these catabolic factors have also
been found in the synovial tissue of patients with OA,
and they predict the development of cartilage destruc-
tion [37]. Interestingly, we also confirmed that in con-
trast to p.1 synovial cells obtained from patients with
moderate-grade synovitis, p.1 synovial cells from pa-
tients with low-grade synovitis are unable to guide the
anti-inflammatory and anti-catabolic effects of ASC, as
found for p.5 synovial cells, as SM were present in very
small numbers.
Conclusions
In summary, our data from in vitro analysis show the
importance of using the correct in vitro cell models to
recreate a milieu that closely resembles OA synovial tis-
sue as the target tissue organ. The availability of in vitro
cell models (p.1 and p.5 synovial cells) with large or
small numbers of SM effectively reflects the different de-
grees of OA, which are characterized by different de-
grees of synovial inflammation, giving the opportunity of
testing cells, anti-inflammatory drugs, or factors in a
well-defined milieu.
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